Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
2 Top Biotech Stocks to Buy Right Now
06:00am, Sunday, 30'th May 2021
One is growing revenue. And the other may soon launch its first product.
The Best Stocks to Invest $3,000 in Right Now
06:06am, Wednesday, 26'th May 2021
Patient investors should make bank from this diverse collection of high-quality businesses.
Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer Study
12:02pm, Tuesday, 25'th May 2021
Exelixis (EXEL) announces encouraging results from the cohort 6 of a phase Ib study of Cabometyx in combination with Tecentriq.
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
07:48am, Tuesday, 25'th May 2021
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination with Roche's Tecentriq (atezolizumab) in pat
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from the metastatic castration-resistant prostate cancer (CRPC) cohort 6 of COSMIC-021, the phase 1b trial of ca
Is Exelixis a Buy?
06:30am, Saturday, 22'nd May 2021
Revenue growth will probably accelerate soon, but it might not be enough.
What Investors Should Look for With Exelixis, DermTech, and Teladoc Health
06:31am, Friday, 21'st May 2021
All three healthcare stocks could have solid growth prospects.
BioNTech, Exelixis, Foot Locker and More Tuesday Afternoon Analyst Calls
11:43am, Tuesday, 18'th May 2021
With the trading day about halfway over, the markets were somewhat mixed on Tuesday.
Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat
02:17pm, Friday, 07'th May 2021
Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.
The Smartest Stocks to Buy With $50 Right Now
05:51am, Friday, 07'th May 2021
You don't need a lot of cash to begin building wealth on Wall Street.
Exelixis (EXEL) CEO Mike Morrissey on Q1 2021 Results - Earnings Call Transcript
03:43am, Friday, 07'th May 2021
Exelixis (EXEL) CEO Mike Morrissey on Q1 2021 Results - Earnings Call Transcript
Exelixis (EXEL) Reports Break-Even Earnings for Q1
08:17pm, Thursday, 06'th May 2021
Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 0.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Exelixis: Q1 Earnings Insights
04:53pm, Thursday, 06'th May 2021
Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year to $0.09, which beat
3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)
05:51am, Thursday, 08'th Apr 2021
These fast-paced companies are on the leading edge of innovation.
Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA
01:41pm, Tuesday, 06'th Apr 2021
The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.
